Background

12544872_ml.jpg

Glycostem has developed a platform technology for the expansion and differentiation of hematopoietic stem and progenitor cells derived from various sources like umbilical cord blood (UCB), bone marow (BM) or mobilized peripheral blood (mPB).

Within the last years, Glycostem's platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells or antigen presenting cells such as dendritic cells.

The technology platform is based on the use of closed bioreactor systems in combination with a proprietary cell culture medium (GBGM - Glycostem Basal Growth Medium) and a patented combination of growth factors.

This technology platform permits the view on new horizon of allogeneic NK cell based immunotherapy ready for prime time.